Related references
Note: Only part of the references are listed.Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
S. E. Dorman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Payam Nahid et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Defining the Optimal Dose of Rifapentine for Pulmonary Tuberculosis: Exposure-Response Relations From Two Phase II Clinical Trials
R. M. Savic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid et al.
CLINICAL INFECTIOUS DISEASES (2016)
Daily Rifapentine for Treatment of Pulmonary Tuberculosis A Randomized, Dose-Ranging Trial
Susan E. Dorman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model
Ian M. Rosenthal et al.
PLOS MEDICINE (2007)
Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis
IM Rosenthal et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Share Paper
